title: [The expression of platelet-derived endothelial cell growth factor in liver cancer].
abstract: OBJECTIVE
  To investigate the expression of platelet-derived endothelial cell growth factor (PD-ECGF) in liver cancer and explore its related intervention with Capecitabine for the growth and metastasis of liver cancer.
  
  
  METHODS
  The protein level of PD-ECGF was determined using immunohistochemical method in 61 HCC samples and the mRNA level was detected using Northern blot analysis. Capecitabine was administered orally in 24 nude mice bearing LCI-D20 tumor. All treatments lasted 3 weeks. The tumor size was calculated by the following formula: V = a x b2 x 0.5. Lung metastasis was evaluated by HE staining in lung samples.
  
  
  RESULTS
  The PD-ECGF expression rate in 61 HCC and paratumoral liver tissues was 70.5% and 47.5%, respectively. The rate was higher in HCC tissues with advanced TNM stage than in those with early TNM stage (81.1% vs 54.2%, P < 0.05). The mRNA level of PD-ECGF was related well to its protein expression. The tumor size on day 3 after last treatment measured in the control, and low dose (1.05 mmol.kg-1.day-1), moderate dose (2.10 mmol.kg-1.day-1) and high dose (3.15 mmol.kg-1.day-1) of Capecitabine treatment groups was 447 mm3 +/- 159 mm3, 414 mm3 +/- 97 mm3, 240 mm3 +/- 119 mm3 and 209 mm3 +/- 150 mm3, respectively. High doses of Capecitabine increased the inhibitory effect on the growth and lung metastasis of HCC implant.
  
  
  CONCLUSIONS
  PD-ECGF is highly expressed in HCC and correlates with the TNM staging. Capecitabine may inhibit the growth and metastasis of HCC.
authors.affiliation: Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, Shanghai 200032, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: Z
authors.initials: Z
authors.lastname: Tang
authors.forename: J
authors.initials: J
authors.lastname: Fan
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D000069287:Capecitabine; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000096:biosynthesis*; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000517:prevention & control; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis*
chemical_list: D000964:Antimetabolites, Antineoplastic; D016228:Endothelial Growth Factors; D010982:Platelet-Derived Growth Factor; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil